Literature DB >> 7724695

Nicotine intake in smokers increases following a single dose of haloperidol.

S Dawe1, C Gerada, M A Russell, J A Gray.   

Abstract

The effects of oral haloperidol on nicotine intake, subjective measures of craving and smoking satisfaction were compared with placebo in light-to-moderate smokers from a post-prandial cigarette and during the subsequent hour of unrestricted smoking. Subjects smoked significantly more, as measured by blood nicotine levels, when they had received haloperidol, although there was no difference between haloperidol and placebo on any subjective measures. These findings may be interpreted to reflect a compensatory increase in smoking in order to obtain the usual nicotine reward. Having achieved usual levels of reward, subjects did not experience a decrease in subjective measures of smoking satisfaction or an increase in nicotine craving.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7724695     DOI: 10.1007/bf02245105

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

1.  Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol.

Authors:  A L Nordström; L Farde; C Halldin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Selective dopamine antagonists reduce nicotine self-administration.

Authors:  W A Corrigall; K M Coen
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  The development and initial validation of a questionnaire on smoking urges.

Authors:  S T Tiffany; D J Drobes
Journal:  Br J Addict       Date:  1991-11

4.  D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.

Authors:  L Farde; F A Wiesel; A L Nordström; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Effects of mecamylamine on human cigarette smoking and subjective ratings.

Authors:  R Nemeth-Coslett; J E Henningfield; M K O'Keeffe; R R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

6.  Prolonged adverse effects of haloperidol in normal subjects.

Authors:  B G Anderson; D Reker; T B Cooper
Journal:  N Engl J Med       Date:  1981-09-10       Impact factor: 91.245

7.  Cocaine-induced reduction of glucose utilization in human brain. A study using positron emission tomography and [fluorine 18]-fluorodeoxyglucose.

Authors:  E D London; N G Cascella; D F Wong; R L Phillips; R F Dannals; J M Links; R Herning; R Grayson; J H Jaffe; H N Wagner
Journal:  Arch Gen Psychiatry       Date:  1990-06

8.  Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man.

Authors:  J I Nurnberger; S Simmons-Alling; L Kessler; S Jimerson; J Schreiber; E Hollander; C A Tamminga; N S Nadi; D S Goldstein; E S Gershon
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Cigarette smoking and subjective response: effects of d-amphetamine.

Authors:  J E Henningfield; R R Griffiths
Journal:  Clin Pharmacol Ther       Date:  1981-10       Impact factor: 6.875

10.  Signs and symptoms of tobacco withdrawal.

Authors:  J R Hughes; D Hatsukami
Journal:  Arch Gen Psychiatry       Date:  1986-03
View more
  19 in total

1.  Aripiprazole therapy for nicotine dependence.

Authors:  Sriram Ramaswamy; Subhash C Bhatia
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 2.  Nicotine and nonnicotine factors in cigarette addiction.

Authors:  Jed E Rose
Journal:  Psychopharmacology (Berl)       Date:  2005-12-16       Impact factor: 4.530

3.  Effects of acute administration of d-amphetamine and haloperidol on procedural learning in man.

Authors:  V Kumari; P J Corr; O F Mulligan; P A Cotter; S A Checkley; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

4.  Effects of nicotine and amphetamine on latent inhibition in human subjects.

Authors:  J C Thornton; S Dawe; C Lee; C Capstick; P J Corr; P Cotter; S Frangou; N S Gray; M A Russell; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

5.  Potent Dopamine D2 Antagonists Block the Reward-Enhancing Effects of Nicotine in Smokers With Schizophrenia.

Authors:  Alexis E Whitton; Alan I Green; Diego A Pizzagalli; Robert M Roth; Jill M Williams; Mary F Brunette
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

Review 6.  The role of antipsychotics in smoking and smoking cessation.

Authors:  Annette M Matthews; Vanessa B Wilson; Suzanne H Mitchell
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

Review 7.  Nicotine: abused substance and therapeutic agent.

Authors:  J Le Houezec
Journal:  J Psychiatry Neurosci       Date:  1998-03       Impact factor: 6.186

8.  Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia.

Authors:  Heidi J Wehring; Stephen J Heishman; Robert P McMahon; Fang Liu; Stephanie Feldman; Heather Raley; Elaine Weiner; Deanna L Kelly
Journal:  J Dual Diagn       Date:  2017 Jan-Mar

9.  Neuroendocrinological and neuropsychological correlates of dopaminergic function in nicotine dependence.

Authors:  Michael N Smolka; Henning Budde; Anne C Karow; Lutz G Schmidt
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

10.  Effects of acute tyrosine/phenylalanine depletion on the selective processing of smoking-related cues and the relative value of cigarettes in smokers.

Authors:  Brian Hitsman; James MacKillop; Anne Lingford-Hughes; Tim M Williams; Faheem Ahmad; Sally Adams; David J Nutt; Marcus R Munafò
Journal:  Psychopharmacology (Berl)       Date:  2007-11-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.